These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21114899)

  • 1. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
    López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
    Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
    Greipp PR; Trendle MC; Leong T; Oken MM; Kay NE; Van Ness B; Kyle RA
    Leuk Lymphoma; 1999 Sep; 35(1-2):83-9. PubMed ID: 10512165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA cell content studies in multiple myeloma.
    San Miguel JF; García-Sanz R; González M; Orfão A
    Leuk Lymphoma; 1996 Sep; 23(1-2):33-41. PubMed ID: 9021683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.
    Morgan RJ; Gonchoroff NJ; Katzmann JA; Witzig TE; Kyle RA; Greipp PR
    Am J Hematol; 1989 Apr; 30(4):195-200. PubMed ID: 2929579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual parameter analysis of myeloma cells by flow cytometry. DNA content of cells containing monotypic cytoplasmic immunoglobulin.
    Chan CS; Wormsley SB; Peter JB; Schechter GP
    Am J Clin Pathol; 1989 Jan; 91(1):12-7. PubMed ID: 2910012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-phase cells of the lymphoplasmocytic compartment in hyperdiploid multiple myeloma are diploid cells.
    Haraldsdóttir V; Haanen C; Kalsbeek-Batenburg E; Olthuis F
    Cytometry; 1995 Oct; 21(2):203-10. PubMed ID: 8582241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-image cytometry and clinical staging systems in multiple myeloma.
    Kropff M; Leo E; Steinfurth G; Esselborn H; Adler CP; Böcking A
    Anticancer Res; 1994; 14(5B):2183-8. PubMed ID: 7840520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
    Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
    Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
    García-Sanz R; Orfão A; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Br J Haematol; 1995 May; 90(1):106-12. PubMed ID: 7786771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.
    Wuilleme S; Robillard N; Lodé L; Magrangeas F; Beris H; Harousseau JL; Proffitt J; Minvielle S; Avet-Loiseau H;
    Leukemia; 2005 Feb; 19(2):275-8. PubMed ID: 15538401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
    Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
    Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations.
    Tafuri A; Meyers J; Lee BJ; Andreeff M
    Cancer; 1991 Jan; 67(2):449-54. PubMed ID: 1985738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotype and DNA cell content in multiple myeloma.
    San Miguel JF; Garcia-Sanz R; Gonzalez M; Orfao A
    Baillieres Clin Haematol; 1995 Dec; 8(4):735-59. PubMed ID: 8845570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ploidy status rarely changes in myeloma patients at disease progression.
    Chng WJ; Winkler JM; Greipp PR; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Ahmann GJ; Henderson K; Blood E; Oken MM; Hulbert A; Van Wier SA; Santana-Dávila R; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R
    Leuk Res; 2006 Mar; 30(3):266-71. PubMed ID: 16111750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
    Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperdiploid myeloma cell as an indicator of poor prognosis and drug refractoriness.
    Hata H; Matsuzaki H; Yoshida M; Sonoki T; Kuribayashi N; Nagasaki A; Kimura T; Harada N; Takatsuki K
    Int J Hematol; 1997 Aug; 66(2):219-26. PubMed ID: 9277053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytology and flow cytometry of malignant effusions of multiple myeloma.
    Palmer HE; Wilson CS; Bardales RH
    Diagn Cytopathol; 2000 Mar; 22(3):147-51. PubMed ID: 10679993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features.
    Montecucco C; Riccardi A; Merlini G; Mazzini G; Giordano P; Danova M; Ascari E
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):81-90. PubMed ID: 6537918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.